Warner-lambert Company

Ortho Pharmaceutical Corporation

Millennium Pharmaceuticals Limited

Leukosite, Inc.

Charles F Schwender

Jagadish C Sircar

David T Connor

Paul C Unangst

Roderick J Sorenson

Brooks R Sunday

Elizabeth A Johnson

John S Kiely

Wiaczeslaw A Cetenko

John H Dodd

Mary E Carethers

Robert F Bruns

Victor T Bandurco

Mark J Suto

Michael P Wachter

William V Murray

Robert Falotico

David Juergen Wustrow

Alfonso J Tobia

Scott A Beers

Stanley Charles Bell

John Shavel, Jr

Walter Newman

Russell E Pike

Charles R Mackay

Elizabeth A Malloy

Keith Demarest

Julia C Pinto

Catherine R Brungardt

Hitesh N Shroff

Daniel L Flynn

Bruce D Roth

Bharat Kalidas Trivedi

Kenneth Gordon Carson

Richard John Booth

James Lawrence Bullington

Wei Wu

Roger F Frechette

Roberta Ellen Glynn

Lisa A Dixon

Wiaczeslaw A Centenko

Aryl alkenamides derivatives as MCP-1 antagonists

Disclosed is a method of treating a subject with a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to the subject a therapeutically effective amount of a compound represented by the following structural formula:

Chemokine receptor antagonists and methods of use therefor

The present invention provides novel compounds comprising peptide sequences which mimic the conserved amino acid motif LDTSL of MAdCAM-1 and which have groups bonded to the N- and C-termini. Also provided are methods of inhibiting the interaction of a cell bearing a ligand of MAdCAM-1, such as human &agr;4&bgr;7, with MAdCAM-1 or a portion thereof (e.g., the extracellular domain), comprising contacting the cell with a compound of the present invention.

Inhibitors of MadCAM-1-mediated interactions and methods of use therefor

The present invention provides novel compounds comprising peptide sequences which mimic the conserved amino acid motif LDTSL and which have groups bonded to the N- and C-termini. Also provided are methods of inhibiting the interaction of a cell bearing a ligand of MAdCAM-1, such as human .alpha.4.beta.7, with MAdCAM-1 or a portion thereof (e.g., the extracellular domain), comprising contacting the cell with a compound of the present invention.

Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor

Benzyl-phosphonate compounds represented by the formula I: ##STR1## are disclosed as useful in treating bone wasting diseases and as an immunosuppresant.

Arylmethylphosphonic acid derivatives useful in treating bone wasting

Tetracyclic compounds having the following structure are described: ##STR1## wherein R.sub.1 -R.sub.10 are as defined. The tetracyclic compounds are capable of potent effects on steroid sensitive tissues and have demonstrated increased uterine weight, antiovulatory effects and potent steroid receptor binding. The compounds have therapeutic utility in reproductive applications such as fertility control, labor induction, ovulation induction and spermatogenesis. Methods for preparing the tetracyclic compounds from substituted indanones are also described.

Substituted dibenz (A F)azulenes and methods of preparation

Novel benzylphosphonate compounds of the general formula I: ##STR1## are disclosed as useful in treating bone wasting diseases including postmenopausal osteoporosis in increasing in mammals bone formation and bone mass.

Trifluoromethybenzylphosphonates useful in treating osteoporosis

Compounds represented by the formula I: ##STR1## are disclosed as agents for use in treating bone wasting diseases.

Substituted phosphonic acids and derivatives useful in treating bone

This invention relates to novel bis-biphenyl substituted 3-mercapto-1,2,4-tetrazoles and to pharmaceutically acceptable salts thereof. The compounds are angiotensin II receptor antagonists, and are useful in treating hypertension (lowering high blood pressure), congestive heart failure, elevated ocular pressure, cerebral stroke, angina, cardiac insufficiency, myocardial infarction or diabetic nephropathy. The invention also relates to a pharmaceutical composition comprising a compound of the invention, a method of treating a physiological condition in a mammal that is mediated by angiotensin II which comprises administering to the mammal an effective amount of a compound of the invention, and novel processes for preparing the compounds of the invention.

Substituted triazoles as angiotensin II inhibitors

Trifluoromethylbenzylphosphonates useful in treating osteoporosis

This invention relates to novel bis-biphenyl substituted 3-mercapto-1,2,4-tetrazoles and to pharmaceutically acceptable salts thereof. The compounds are angiotensin II receptor antagonists, and are useful in treating hypertension (lowering high blood pressure), congestive heart failure, elevated ocular pressure, cerebral stroke, angina, cardiac insufficiency, myocardial infection or diabetic nephropathy. The invention also relates to pharmaceutical composition comprising a compound of the invention, a method of treating a physiological condition in a mammal that is mediated by angiotensin II which comprises administering to the mammal an effective amount of a compound of the invention, and novel processes for preparing the compounds of the invention.

Novel purine derivatives are described as agents for treating autoimmune diseases as well as a method of manufacture and pharmaceutical compositions as well as novel intermediates in the manufacture thereof.

Purine derivatives

Novel pyrido[2,3-f] [1,4]thiazepines and novel pyrido[3,2-b] [1,5]benzothiazepines of the formula: ##STR1## These compounds are useful as calcium channel antagonists with cardiovascular, antiasthmatic and antibronchoconstriction activity. Also described are methods of producing the novel compounds and intermediates thereof.

Novel pyrido[2,3-f](1,4)thiazepines and

Growing community of inventors

Califon, NJ, United States of America

Charles F Schwender